ATXS
Price
$4.04
Change
-$0.02 (-0.49%)
Updated
Apr 11 closing price
Capitalization
227.99M
26 days until earnings call
DNLI
Price
$12.70
Change
+$0.20 (+1.60%)
Updated
Apr 11 closing price
Capitalization
1.84B
31 days until earnings call
Ad is loading...

ATXS vs DNLI

Header iconATXS vs DNLI Comparison
Open Charts ATXS vs DNLIBanner chart's image
Astria Therapeutics
Price$4.04
Change-$0.02 (-0.49%)
Volume$380.57K
Capitalization227.99M
Denali Therapeutics
Price$12.70
Change+$0.20 (+1.60%)
Volume$1.63M
Capitalization1.84B
ATXS vs DNLI Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. DNLI commentary
Apr 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and DNLI is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 12, 2025
Stock price -- (ATXS: $4.04 vs. DNLI: $12.70)
Brand notoriety: ATXS and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 130% vs. DNLI: 119%
Market capitalization -- ATXS: $227.99M vs. DNLI: $1.84B
ATXS [@Biotechnology] is valued at $227.99M. DNLI’s [@Biotechnology] market capitalization is $1.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 4 bearish.
  • DNLI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а -13.21% price change this week, while DNLI (@Biotechnology) price change was +7.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.15%. For the same industry, the average monthly price growth was -16.20%, and the average quarterly price growth was -17.21%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+0.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.84B) has a higher market cap than ATXS($228M). DNLI YTD gains are higher at: -37.684 vs. ATXS (-54.810). ATXS has higher annual earnings (EBITDA): -111.56M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. ATXS (328M). ATXS has less debt than DNLI: ATXS (5.35M) vs DNLI (48.7M). ATXS (0) and DNLI (0) have equivalent revenues.
ATXSDNLIATXS / DNLI
Capitalization228M1.84B12%
EBITDA-111.56M-492.89M23%
Gain YTD-54.810-37.684145%
P/E RatioN/AN/A-
Revenue00-
Total Cash328M832M39%
Total Debt5.35M48.7M11%
FUNDAMENTALS RATINGS
ATXS vs DNLI: Fundamental Ratings
ATXS
DNLI
OUTLOOK RATING
1..100
6960
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9438
PRICE GROWTH RATING
1..100
9689
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (62) in the Biotechnology industry is in the same range as DNLI (94). This means that ATXS’s stock grew similarly to DNLI’s over the last 12 months.

ATXS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that ATXS’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (38) in the Biotechnology industry is somewhat better than the same rating for ATXS (94). This means that DNLI’s stock grew somewhat faster than ATXS’s over the last 12 months.

DNLI's Price Growth Rating (89) in the Biotechnology industry is in the same range as ATXS (96). This means that DNLI’s stock grew similarly to ATXS’s over the last 12 months.

DNLI's P/E Growth Rating (97) in the Biotechnology industry is in the same range as ATXS (100). This means that DNLI’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSDNLI
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 11 days ago
82%
Bullish Trend 16 days ago
79%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 5 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
75%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSCIX35.62N/A
N/A
abrdn US Small Cap Equity Inst
JSCRX16.30N/A
N/A
PGIM Jennison Small Company R
LYRAX23.57N/A
N/A
Lyrical US Value Equity A
PREIX138.55N/A
N/A
T. Rowe Price Equity Index 500
BFIIX16.17N/A
N/A
Baron FinTech Institutional

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KYMR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-0.49%
KYMR - ATXS
50%
Loosely correlated
+7.68%
XENE - ATXS
49%
Loosely correlated
+2.18%
DNLI - ATXS
49%
Loosely correlated
+1.60%
TRDA - ATXS
49%
Loosely correlated
+0.64%
IMNM - ATXS
48%
Loosely correlated
+14.52%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RCKT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+1.60%
RCKT - DNLI
60%
Loosely correlated
+6.68%
BEAM - DNLI
58%
Loosely correlated
+5.74%
NTLA - DNLI
56%
Loosely correlated
+9.45%
CRSP - DNLI
54%
Loosely correlated
+14.71%
RGNX - DNLI
54%
Loosely correlated
+8.87%
More